July 19, 2011 — The US Food and Drug Administration (FDA) has approved imiquimod 2.5% cream (Zyclara, Graceway Pharmaceuticals, LLC) for the treatment of actinic keratoses (AK). The drug manufacturer ...
Compounded imiquimod 5% ointment may be safe and effective for diffuse conjunctival melanoma in situ (MIS) or ocular surface squamous neoplasia (OSSN), according to a case series study published ...
Imiquimod 5% cream has shown promise as a treatment for superficial basal cell carcinomas and, in pilot studies, for actinic keratoses (AKs). In this manufacturer-supported, randomized, double-blind, ...
BRISTOL, Tenn., March 26 Graceway® Pharmaceuticals announced today that the Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for Zyclara(TM), determining it to be safe ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Five years after treatment, results showed a freedom ...
MELVILLE, N.Y., Feb. 25 /PRNewswire/ -- E. Fougera & Co., a leading specialty pharmaceutical manufacturer, today announced it has received first generic approval from the FDA for Imiquimod Cream 5% ...
HAWTHORNE, N.Y.--(BUSINESS WIRE)-- Taro Pharmaceutical Industries Ltd. (“Taro,” or the “Company,” Pink Sheets: TAROF) reported today that it has received approval from the U.S. Food and Drug ...
Surgical treatment of vulvar intraepithelial neoplasia (VIN) can cause disfigurement of the vulva and does not always prevent recurrence or progression because the most common cause of these lesions, ...
A compounded form of imiquimod, a topical immune response modifier, showed promise as a treatment for ocular surface malignancies in a small case series. The drug appeared fairly safe, although with a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results